To include your compound in the COVID-19 Resource Center, submit it here.

Broken-field runner

Why Receptos may have room to run after $500M run-up on Phase II MS data

Receptos Inc. (NASDAQ:RCPT) already has added more than $500 million in market cap on its Phase II MS data, but a look at how the market previously rewarded Biogen Idec Inc. (NASDAQ:BIIB) for Phase III data for a competing MS drug suggest Receptos could have even more room to

Read the full 499 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE